Related Experiment Video

Updated: Jul 11, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy

Douglas L Mann1, Michael A Acker, Mariell Jessup

  • 1Baylor College of Medicine, Houston, Texas, USA. dmann@bcm.tmc.edu

The Annals of Thoracic Surgery
|September 25, 2007
PubMed

Insights

The CorCap Cardiac Support Device (CSD) reduces adverse outcomes in heart failure by attenuating left ventricular remodeling. This implantable device improved patient outcomes and reduced the need for cardiac procedures in the Acorn trial.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Left ventricular (LV) remodeling is a significant contributor to adverse outcomes in heart failure patients.
  • The CorCap Cardiac Support Device (CSD) is designed to mitigate LV remodeling.
  • Understanding the impact of CSD on heart failure progression is crucial.

Purpose of the Study:

  • To assess the safety and efficacy of the CorCap Cardiac Support Device (CSD) in patients with heart failure.
  • To evaluate the CSD's effect on clinical outcomes and LV remodeling.
  • To determine if CSD implantation improves the natural history of heart failure.

Main Methods:

  • The Acorn trial randomized 300 heart failure patients into two groups: those needing mitral surgery and those not.
  • Patients were assigned to either standard treatment or standard treatment plus CSD implantation.
  • The primary endpoint combined vital status, major cardiac procedures for heart failure, and New York Heart Association (NYHA) class.

Main Results:

  • The CSD group showed a statistically significant benefit in the primary endpoint (proportional odds ratio = 1.73, p = 0.024).
  • CSD patients experienced fewer cardiac procedures and improved NYHA class (p = 0.049).
  • Significant reductions in LV end-diastolic and end-systolic volumes and increased LV sphericity were observed in the CSD group, with no significant increase in adverse events.

Conclusions:

  • The Acorn trial results support the use of CSD to prevent LV remodeling in heart failure.
  • The CSD favorably impacts the natural history of heart failure by attenuating adverse remodeling.
  • CSD implantation is a promising therapeutic strategy for managing heart failure patients.
Abstract

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...